NR1H4 and metabolic dysfunction-associated steatohepatitis: For example, obeticholic acid (farnesoid X receptor (FXR) agonist), one of the potential therapies for NASH in clinical trials (3), almost completely depletes the liver of retinyl palmitate in animal models (45); this is a potential danger signal, as the liver is the major storage site in the body for vitamin A (46).